GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Median PS Value
中文

TransMedics Group (TransMedics Group) Median PS Value

: $0.00 (As of Today)
View and export this data going back to 2019. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. TransMedics Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.423. TransMedics Group's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-24), TransMedics Group's share price is $90.53. TransMedics Group's Median PS Value is $0.00. Therefore, TransMedics Group's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for TransMedics Group's Median PS Value or its related term are showing as below:

TMDX's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.79
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

TransMedics Group Median PS Value Historical Data

The historical data trend for TransMedics Group's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

TransMedics Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Medical Devices subindustry, TransMedics Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group Price-to-Median-PS-Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where TransMedics Group's Price-to-Median-PS-Value falls into.



TransMedics Group Median PS Value Calculation

TransMedics Group's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=7.423*0
=0.00

10-Year Median PS Ratio is 0.
TransMedics Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.423.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group  (NAS:TMDX) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

TransMedics Group's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=90.53/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group Median PS Value Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


TransMedics Group (TransMedics Group) Business Description

Traded in Other Exchanges
Address
200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.
Executives
Tamer I Khayal officer: Chief Commercial Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost officer: VP of US Regulatory & FDA Rel. 2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein director, officer: President & CEO TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon officer: Chief Financial Officer 200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill director 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile director 200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey officer: VP of Operations 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme officer: VP, Clinical Affairs C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr director
Rakesh P. Godhani officer: Chief Digital Officer C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan officer: VP of Quality & Engineering 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810